COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Patients with covid 19 infection will receive standard treatment of Atazanavir/Ritonavirdrug 300/100 mg (Razavi Pharmaceutical Institute) once daily in addition to
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: all admitted patients with covid -19 infection based on clinical findings ,PCR or lung CT abnormality consistent with covid-19 spo2 bellow 93 mmHg age above 18 years old
Exclusion criteria
Exclusion criteria: patient rejection history of antipsycotic use history of seizure, dementia and parkinson disease Hx of liver disease Hx of feochromocytoma allergy to phenothiazines drug any drug interaction between patients medicines and chlorpromazine pregnancy and lactation Hx of covid treatments bradycardia < 60 /min multi-organ failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients level of Spo2. Timepoint: daily. Method of measurement: puls oximetr. | — |
Secondary
| Measure | Time frame |
|---|---|
| Need to ICU admission. Timepoint: During the study. Method of measurement: Follow up of patient and documentation of the ICU admission.;Days stayed in the Intensive Care Unit. Timepoint: During the study. Method of measurement: Documenting the days stayed in the Intensive Care Unit.;Days stayed in the hospital. Timepoint: At the end of the study. Method of measurement: Documentation of the hospital stay according to patients chart.;Mortality rate. Timepoint: At the end of the study. Method of measurement: Follow up of patients and documentation of the mortality. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEbrahim Salehifar
Mazandaran University of Medical Sciences
Outcome results
None listed